Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QuantiFERON-CMV guided pre-emptive CMV monitoring after kidney transplantation
ACTRN12618000913279Phase 4Active, not recruiting
- Sponsor
- associate Prof. Tomas Reischig, M.D., Ph.D.
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of valganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by associate Prof. Tomas Reischig, M.D., Ph.D. Primary endpoints: Cumulative incidence of high-grade CMV infection and Moderate-to-severe interstitial fibrosis/tubular atrophy. Started Jun 2018; status: active, not recruiting.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ACTRN12618000913279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000913279.